Rare NF1 microdeletion syndrome in an Omani patient

Musallam Al-Araimi1 | Nishath Hamza1 | Ali Al Yahmadi1 | Hiba Al Mazrooei1 | Afaf Elsheikh1 | Amira Al Amri1 | Salma Al Harrasi1 | Lena Hausdorf2 | Waad-Allah Mula-Abed1

1 National Genetic Center, Royal Hospital, Ministry of Health, Muscat, Oman
2 Centogene AG, Rostock, Germany

Correspondence
Musallam Al‐Araimi, National Genetic Center, Royal Hospital, Ministry of Health, Muscat, Oman.
Email: musallam95@yahoo.com

1 SHORT REPORT

We present a first case report from Oman of a 20-month-old male child presenting with a neurofibromatosis-1 phenotype combined with webbed neck and short stature. Comprehensive molecular testing revealed a de novo germ-line heterozygous 1.7 Mb microdeletion at 17q11.2, which lead to the diagnosis of NF1 microdeletion syndrome.

We present a case of a 20-month-old male child, born prematurely (33 weeks) with IUGR (intrauterine growth restriction) after elective cesarean section to a mother who had a history of a previous abortion and one healthy offspring. The index patient presented here was the product of a non-consanguineous marriage and has no family history of dysmorphic or disability syndromes. After birth, the patient was admitted to the neonatal intensive unit for 25 days. He initially presented with abnormal facial features and developmental delay and was referred to our center for further evaluation and management at 2 years of age. Along with delayed development, the patient mainly presented with the clinical features in Table 1, which were highly suggestive of Neurofibromatosis Type 1 (NF1) associated with mutations in the NF1 gene.

The patient also exhibited short stature, webbed neck, and cardiac defect at birth, (which resolved with time) all symptoms which are commonly seen in Noonan syndrome (NS) patients. This led to a preliminary diagnosis of Neurofibromatosis-Noonan syndrome (NFNS) in this patient (Figure 1).

NFNS is typically described as a rare autosomal dominant disorder with combined clinical features of NF1 and Noonan syndrome (NS).1 To confirm this diagnosis, the patient was referred for molecular genetic testing to the laboratory at our center where the patient’s blood was collected after informed parental consent. DNA was extracted from the patient’s blood and processed for next-generation sequencing (NGS) using the Ion AmpliSeq Comprehensive Cancer panel (CCP) on the Ion S5 from Ion Torrent (ThermoFisher Scientific) to probe for mutations in the NF1 gene and three of the most significant genes causing NS, namely PTPN11, SOS1, and KRAS. Since the CCP is also validated in our laboratory for use as a preliminary screen for copy number variants above 200 kb, we were able to detect an apparent 279 kb deletion at the 17q11.2 (hg19) locus using NGS. This 279 kb deleted region indicated a single copy loss for five non-consecutive genes present within the 17q11.2 locus, including the NF1 gene. This signified the presence of a microdeletion event at this locus. However, NGS cannot reliably provide information regarding the full extent of microdeletions or their breakpoints because NGS results only
reflect the genes probed by the specific panel, which are likely less than the actual number of genes or regions deleted.

In view of establishing the diagnosis of neurofibromatosis, we used the Multiplex ligation probe amplification (MLPA) kits from MRC Holland (P081-D1 and P082-C2) to confirm the complete heterozygous NF1 gene deletion (exons 1-58) in the index patient. Since the index patient presented with webbed neck and relatively severe developmental delay, features rarely seen in NF1 patients, we further sought to delineate the microdeletion breakpoint regions and characterize the genes in the deleted locus. The patient DNA was processed for comparative genomic hybridization (CGH) array on the Affymetrix platform using the CytoScan HD kit, and data analysis was carried out using the CHAS software (v.3.1.0.15). CGH array analysis revealed a heterozygous microdeletion of almost 1.7 Mb in the distal part of chromosome 17 (17q11.2) in the index patient. This 1.7 Mb microdeletion region [arr[hg19]17q11.2(28,838,381-30,533,034) x1] actually included 22 genes, of which 11 were OMIM genes [CRLF3 (614853), ATAD5 (609534), ADAP2 (608635), RNF135 (611358), NF1 (613113), OMG (164345), EVI2B (158381), EVI2A (158380), RAB11FIP4 (611999), MIR193A (614733), SUZ12 (606245)]. Out of these 11 OMIM genes, only two genes, RNF135 and NF1 were associated with disease phenotypes. A previous study on a patient with haploinsufficiency of the RNF135 gene due to a microdeletion encompassing RNF135 and another four genes, but excluding NF1, suggested that haploinsufficiency of RNF135 may contribute to the overgrowth, facial dysmorphism, learning disabilities and other congenital anomalies exhibited by patients with NF1 microdeletions. However, despite the absence of one RNF135 gene copy, our patient did not show any overgrowth symptoms, although facial dysmorphism was noted. On the contrary, the patient continued to exhibit short stature till last clinical visit 8 months ago.

| TABLE 1 | Abnormalities observed in the index patient |
|-----------------------------|---------------------------------|
| **NF1 phenotype**         | Widely spaced nipples (internipple distance = 13.9 cm; >97 percentile at age 3 y) |
| Multiple café au lait macules | Pectus deformity                 |
| Nevi anemicus             | Ophthalmology investigations    |
| Large hands and feet     | Two lisch nodules in each eye   |
| Single juvenile xanthogranuloma | Retinal pigmenatry epithelial changes close to optical disk in left eye |
| Potosis                   | Other investigations            |
| Thick skin               | Chromosomal karyotyping: 46, XY |
| High-arched palate       | Echocardiogram: Normal at last evaluation |
| Low set ears             | Whole Spin X-ray: Inferior peaking of upper lumbar vertebrae |
| Broad forehead           | CT Brain: Normal                |
| Down-sloping palpebral fissures | NS-like phenotype              |
| Depressed nasal bridge   | Kyphosis                        |
| Kyphosis                 | Webbed neck                     |
| Hypertelorism            | Short stature                   |
| Other investigations     | Cardiac anomaly at birth (resolved with time) |

FIGURE 1  NFNS presentation in the index patient (A) café au lait spots, pectus deformity, and widely spaced nipples (B) large café au lait spot on the inner thigh (C) nevus anemicus (D) webbed neck, large feet, and hands (E) Juvenile xanthogranuloma
Given the preliminary diagnosis of NFNS, we sought to rule out Noonan syndrome by analyzing all the associated genes (A2ML1, BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, SOS1, SPRED1) using a custom NGS panel. However, no pathogenic or candidate variants were detected in these genes. Hence, our comprehensive testing resulted in revising the diagnosis from NFNS to NF1 microdeletion syndrome in our patient; the first such case to be reported in Oman. Although a 1.7 Mb microdeletion associated with the NF1 gene was previously reported elsewhere using the FISH technique in 1999, it was present in mosaic form. Moreover, the range of the region and the genes deleted were not well defined, likely due to the lack of advanced CGH array technology at the time.

It is not surprising that patients with mutations in the NF1 gene can also present with features overlapping with those seen in NS patients, considering that both the NF1 gene and the NS genes express proteins which are integral components of the RAS-MAPK developmental pathways during embryogenesis. Also, the complete loss of one of the alleles of the NF1 gene is the probable cause of the relatively more severe and earlier presentation of cognitive abnormalities and dysmorphism in our patient, a phenomenon also observed in previous reports of NF1 microdeletions.

Although SNP analysis using array CGH indicated that the microdeleted allele was maternal in origin, no genomic abnormality was detected in either parent. Hence, we concluded that this 1.7 Mb microdeletion within the 17q11.2 region probably occurred as a de novo event. The clinical management protocol adopted for this patient was based on the international guidelines for NF1 patients, which primarily focus on the evaluation and treatment of complications. We referred the patient to appropriate specialists as part of a management plan to include regular clinical evaluation, assessment of developmental milestones and annual ophthalmologic examination to enable early or preventive interventions. A periodic follow-up using magnetic resonance imaging (MRI) for potential intracranial tumors and other internal tumors was also implemented.

**CONFLICT OF INTEREST**

The authors of this manuscript have no conflict of interests to declare.

**AUTHOR CONTRIBUTION**

MA: conducted clinical sampling, patient counseling, and manuscript review. NH: carried out molecular genetic analyses and wrote the manuscript. AAY, HAM, AE, AAA: carried out cytogenetic and molecular cytogenetic analyses. SAH: supervised cytogenetic work. LH: carried out molecular genetic work-up. WM: carried out manuscript review.

**ORCID**

Musallam Al-Araimi [http://orcid.org/0000-0002-8705-8461]

**REFERENCES**

1. De Luca A, Bottillo I, Sarkozy A, et al. NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. *Am J Hum Genet*. 2005;77:1092-1101.
2. Douglas J, Cilliers D, Coleman K, et al. Mutations in RNF135, a gene within the NF1 microdeletion region, cause phenotypic abnormalities including overgrowth. *Nat Genet*. 2007;39:963-965.
3. Streubel B, Latta E, Kehrer-Sawatzki H, Hoffmann GF, Fonatsch C, Rehder H. Somatic mosaicism of a greater than 1.7-Mb deletion of genomic DNA involving the entire NF1 gene as verified by FISH: further evidence for a contiguous gene syndrome in 17q11.2. *Am J Med Genet*. 1999;87:12-16.
4. Tidyman WE, Rauen KA. The RASopathies: Developmental syndromes of Ras/MAPK pathway dysregulation. *Curr Opin Genet Dev*. 2009;19:230-236.
5. Xie B, Fan X, Lei Y, et al. A novel de novo microdeletion at 17q11.2 adjacent to NF1 gene associated with developmental delay, short stature, microcephaly and dysmorphic features. *Mol Cytogenet*. 2016;31:9-41.
6. Cnossen MH, van der Est MN, Breuning MH, et al. Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type 1? *Hum Mutat*. 1997;9:458-464.
7. Jenne DE, Tinschert S, Reimann H, et al. Molecular characterization and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 deletions. *Am J Hum Genet*. 2001;69:516-527.
8. Kayes LM, Burke W, Riccardi VM, et al. Deletions spanning the neurofibromatosis I gene: identification and phenotype of five patients. *Am J Hum Genet*. 1994;54:424-436.
9. Mautner VF, Kluwe L, Friedrich RE, et al. Clinical characterization of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions. *J Med Genet*. 2010;47:623-630.
10. Hersh JH. Health supervision for children with neurofibromatosis. *Pediatrics*. 2008;121:633-642.
11. Radtke HB, Sebold CD, Allison C, Haidle JL, Schneider G. Neurofibromatosis type 1 in genetic counseling practice: recommendations of the National Society of Genetic Counselors. *J Genet Couns*. 2007;16:387-407.

How to cite this article: Al-Araimi M, Hamza N, Al Yahmadi A, et al. Rare NF1 microdeletion syndrome in an Omani patient. *Clin Case Rep*. 2018;6:2424-2426. [https://doi.org/10.1002/ccr3.1881](https://doi.org/10.1002/ccr3.1881)